A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

Completed · Phase 3 · Has a placebo group

Conditions studied: Transient Insomnia

In brief

The purpose of this study is to to assess the effect of gabapentin compared to placebo on sleep, using polysomnography along with subjective sleep assessments, in subjects with transient insomnia induced by a sleep phase advance.

Key facts

Study ID

NCT00163046

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

256

Starts

2005-10-01

Expected to finish

2006-04-01

Last updated by the study team

2021-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older with occasional sleeplessness in the month prior to screening

You may not qualify if…

• Current treatment for, or recent history (within 2 years) of, a sleeping disorder including excessive snoring, obstructive sleep apnea or a chronic painful condition that interferes with the subject's sleep
• Currently taking or expected to take any of the following during trial: amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene, barbiturates, and phencyclidine during their participation in the trial

Where it is running

• Pfizer Investigational Site — Glendale, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.